334 related articles for article (PubMed ID: 37284793)
1. Characteristics of amnestic patients with hypometabolism patterns suggestive of Lewy body pathology.
Silva-Rodríguez J; Labrador-Espinosa MA; Moscoso A; Schöll M; Mir P; Grothe MJ;
Brain; 2023 Nov; 146(11):4520-4531. PubMed ID: 37284793
[TBL] [Abstract][Full Text] [Related]
2. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
[TBL] [Abstract][Full Text] [Related]
3. Differential Effects of Tau Stage, Lewy Body Pathology, and Substantia Nigra Degeneration on
Silva-Rodríguez J; Labrador-Espinosa MA; Moscoso A; Schöll M; Mir P; Grothe MJ;
J Nucl Med; 2023 Feb; 64(2):274-280. PubMed ID: 36008119
[TBL] [Abstract][Full Text] [Related]
4. Clinical profiles of dementia with Lewy bodies with and without Alzheimer's disease-like hypometabolism.
Chiba Y; Fujishiro H; Ota K; Kasanuki K; Arai H; Hirayasu Y; Sato K; Iseki E
Int J Geriatr Psychiatry; 2015 Mar; 30(3):316-23. PubMed ID: 24839913
[TBL] [Abstract][Full Text] [Related]
5. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
[TBL] [Abstract][Full Text] [Related]
6. Biomarker-based stability in limbic-predominant amnestic mild cognitive impairment.
Tondo G; Carli G; Santangelo R; Mattoli MV; Presotto L; Filippi M; Magnani G; Iannaccone S; Cerami C; Perani D;
Eur J Neurol; 2021 Apr; 28(4):1123-1133. PubMed ID: 33185922
[TBL] [Abstract][Full Text] [Related]
7. Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: an individual approach exploring clinical-biomarker mismatches and sociodemographic parameters.
Coutinho AM; Busatto GF; de Gobbi Porto FH; de Paula Faria D; Ono CR; Garcez AT; Squarzoni P; de Souza Duran FL; de Oliveira MO; Tres ES; Brucki SMD; Forlenza OV; Nitrini R; Buchpiguel CA
Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2666-2680. PubMed ID: 32055966
[TBL] [Abstract][Full Text] [Related]
8. A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer's disease, and mild cognitive impairment using brain 18F-FDG PET.
Etminani K; Soliman A; Davidsson A; Chang JR; Martínez-Sanchis B; Byttner S; Camacho V; Bauckneht M; Stegeran R; Ressner M; Agudelo-Cifuentes M; Chincarini A; Brendel M; Rominger A; Bruffaerts R; Vandenberghe R; Kramberger MG; Trost M; Nicastro N; Frisoni GB; Lemstra AW; van Berckel BNM; Pilotto A; Padovani A; Morbelli S; Aarsland D; Nobili F; Garibotto V; Ochoa-Figueroa M
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):563-584. PubMed ID: 34328531
[TBL] [Abstract][Full Text] [Related]
9. Differential patterns of regional cerebral hypometabolism according to the level of cerebral amyloid deposition in patients with amnestic mild cognitive impairment.
Jeon SY; Yi D; Byun MS; Choi HJ; Kim HJ; Lee JH; Baek H; Choe YM; Lee Y; Woo JI; Lee DY
Neurosci Lett; 2016 Oct; 632():104-8. PubMed ID: 27574728
[TBL] [Abstract][Full Text] [Related]
10. Comparison of dynamic susceptibility contrast enhanced MR and FDG-PET brain studies in patients with Alzheimer's disease and amnestic mild cognitive impairment.
Wabik A; Trypka E; Bladowska J; Statkiewicz M; Sąsiadek M; Zimny A
J Transl Med; 2022 Jun; 20(1):259. PubMed ID: 35672750
[TBL] [Abstract][Full Text] [Related]
11. A biomarker study in long-lasting amnestic mild cognitive impairment.
Cerami C; Dodich A; Iannaccone S; Magnani G; Santangelo R; Presotto L; Marcone A; Gianolli L; Cappa SF; Perani D
Alzheimers Res Ther; 2018 Apr; 10(1):42. PubMed ID: 29695292
[TBL] [Abstract][Full Text] [Related]
12. Biomarker-Based Prediction of Progression to Dementia: F-18 FDG-PET in Amnestic MCI.
Tripathi M; Tripathi M; Parida GK; Kumar R; Dwivedi S; Nehra A; Bal C
Neurol India; 2019; 67(5):1310-1317. PubMed ID: 31744965
[TBL] [Abstract][Full Text] [Related]
13. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
[TBL] [Abstract][Full Text] [Related]
14. Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease.
Strom A; Iaccarino L; Edwards L; Lesman-Segev OH; Soleimani-Meigooni DN; Pham J; Baker SL; Landau SM; Jagust WJ; Miller BL; Rosen HJ; Gorno-Tempini ML; Rabinovici GD; La Joie R;
Brain; 2022 Apr; 145(2):713-728. PubMed ID: 34373896
[TBL] [Abstract][Full Text] [Related]
15. Clinical, Neuropsychological, and Neuroimaging Characteristics of Amyloid- positive vs. Amyloid-negative Patients with Clinically Diagnosed Alzheimer's Disease and Amnestic Mild Cognitive Impairment.
Wang Y; Lou F; Li Y; Liu F; Wang Y; Cai L; Gordon ML; Zhang Y; Zhang N
Curr Alzheimer Res; 2021; 18(6):523-532. PubMed ID: 34598664
[TBL] [Abstract][Full Text] [Related]
16. Syndrome-specific patterns of regional cerebral glucose metabolism in posterior cortical atrophy in comparison to dementia with Lewy bodies and Alzheimer's disease--a [F-18]-FDG pet study.
Spehl TS; Hellwig S; Amtage F; Weiller C; Bormann T; Weber WA; Hüll M; Meyer PT; Frings L
J Neuroimaging; 2015; 25(2):281-288. PubMed ID: 24593796
[TBL] [Abstract][Full Text] [Related]
17. Effect of Alzheimer's Disease and Lewy Body Disease on Metabolic Changes.
Lee YH; Jeon S; Yoo HS; Chung SJ; Jung JH; Baik K; Sohn YH; Lee PH; Yun M; Evans AC; Ye BS
J Alzheimers Dis; 2021; 79(4):1471-1487. PubMed ID: 33459638
[TBL] [Abstract][Full Text] [Related]
18. Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria.
Caminiti SP; Sala A; Iaccarino L; Beretta L; Pilotto A; Gianolli L; Iannaccone S; Magnani G; Padovani A; Ferini-Strambi L; Perani D
Alzheimers Res Ther; 2019 Feb; 11(1):20. PubMed ID: 30797240
[TBL] [Abstract][Full Text] [Related]
19. FDG-PET markers of heterogeneity and different risk of progression in amnestic MCI.
Caminiti SP; De Francesco S; Tondo G; Galli A; Redolfi A; Perani D; ;
Alzheimers Dement; 2024 Jan; 20(1):159-172. PubMed ID: 37505996
[TBL] [Abstract][Full Text] [Related]
20. Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects.
Coutinho AM; Porto FH; Duran FL; Prando S; Ono CR; Feitosa EA; Spíndola L; de Oliveira MO; do Vale PH; Gomes HR; Nitrini R; Brucki SM; Buchpiguel CA
Alzheimers Res Ther; 2015 Sep; 7(1):58. PubMed ID: 26373380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
